Regeneron Pharmaceuticals, Inc is a biotechnology company headquartered in the United States. Founded in 1988 and led by physician-scientists, the firm focuses on inventing, developing, and commercializing medicines for serious diseases. Its scientific workforce includes over 1,400 team members with MDs and/or PhDs, and the company maintains a global operational network.
The company's technical capabilities span antibody discovery, fully human and bispecific antibodies, genetics, and genetic medicine. Its proprietary VelociSuite® technologies produce optimized fully human antibodies and new classes of bispecific antibodies. The Regeneron Genetics Center® (RGC) works to pioneer data-powered insights for the next frontier of medicine.
With more than 35 years in operation, Regeneron employs over 15,000 people. The company's culture emphasizes a relentless focus on science.
